Hormonally Balanced review

Its tirzepatide program advertises $475 per month in October 2026. That is a real public offer, with medication and several care services described, but it is not a verified bill for every dose or treatment duration. The separate semaglutide page describes a 12-week injectable program without a readable numeric price. Do not carry the tirzepatide amount over to semaglutide or assume twelve weeks is billed as three equal monthly installments. Both pages describe private-pay care and say insurance is not accepted. For a usable comparison, the quote needs to identify the medicine, dose, quantity, formulation, treatment period and amount due at the first payment. It should also distinguish any further care, testing or supply charges. That lets you compare the amount actually committed for the same treatment period, rather than treating a monthly headline as proof of an all-inclusive, cancel-anytime arrangement. The advertised amount does not confirm the bill you would be asked to authorize.

The tirzepatide page describes an initial physician-assistant telehealth consultation, medication delivery, coach check-ins, a journal, prescription management, shipping and handling, and unlimited practitioner consultations. It says appointments are usually available within 2–3 business days. These are useful care details, but typical appointment availability is not a guarantee of immediate treatment, a response deadline or a shipping promise. Unlimited consultations also does not identify which clinician responds or how consultations are arranged. The semaglutide page separately describes consultation, a prescription and journal, and staff check-in calls; it does not establish the same complete fee and inclusion schedule. Someone choosing between the two programs should compare the actual follow-up arrangement as well as the medication. In particular, clarify who reviews progress, how a dose change is authorized and which questions go to the prescriber rather than a coach. The included journal and coaching do not replace a product-specific treatment plan or make a particular weight-loss outcome predictable.

The current homepage identifies Dr. Andrew Lenhardt as Chief Medical Officer and Rachel Venable and Mary Stratos as co-lead physician assistants. Those are the clinic's published roles, not a fresh independent license check or proof that any one of them will manage your care. An older team page still carries different biographies and a historical physician disclaimer, so it should not be used to describe today's team as having only one physician named in a footer. The inconsistency is a reason to confirm your actual practice and treating clinician, rather than combine the old and new names into an assumed current team. The homepage's physician-led and bloodwork-based descriptions explain the clinic's positioning, but they do not establish the scope of every appointment. Ask who performs the initial assessment, who prescribes, who reviews tests and how to reach that person during follow-up. A leadership title, staff biography and your individual care assignment are separate facts.

The clinic emphasizes bloodwork-based care and describes diagnostic lab evaluation, but the public material does not establish a funded baseline panel, a repeat-test allowance or payment of collection charges within the weight-loss fee. The homepage's discussion of hormone panels also does not mean every weight-loss patient receives the same tests. Before treating the advertised amount as the full cost, obtain the required panel for your selected program, where it can be collected and which organization will send the bill. If you already have recent results, ask whether the clinician can use them and whether that changes any fee; do not assume an outside result automatically replaces the clinic's requirements. The important distinction is between medical review of bloodwork and payment for obtaining it. A consultation can involve lab interpretation while the laboratory still bills separately. Continuing treatment may require further assessment, so the initial quote should address repeat testing as well as the first visit.

Hormonally Balanced has substantive website terms marked revised December 2024. They are not an empty page, but they also do not supply the complete financial agreement for a selected medication program. The readable terms leave the applicable automatic-renewal authorization, cancellation notice, pending-medication cutoff and clinical-denial refund unresolved; a governing-state placeholder also remains. The 12-week program description does not itself say whether payment is prepaid, collected in installments or refundable if treatment stops. Before committing, establish when the next charge occurs, how a cancellation becomes effective and which medication charges become final after prescribing or processing. Also distinguish a canceled future renewal from a request to recover an amount already collected. A free discovery call is a way to discuss the offering, not a contractual refund promise or free clinical treatment. Keep the actual care agreement and itemized payment terms so the commitment is clear beyond the website's general monthly advertising.

The current homepage names Massachusetts, California, Texas, Florida, New York, Rhode Island and New Hampshire, while also using national branding. The terms limit services to states where the clinicians are licensed. Neither wording proves every drug is available in every state or that a listed state remains suitable when you travel. Confirm eligibility using your treatment and physical location during care. Medication fulfillment needs its own details: the tirzepatide page includes shipping and handling, but does not identify the selected dispenser, brand-versus-compound formulation, concentration or a guaranteed arrival interval. The semaglutide page mentions compounding pharmacies generally without assigning a particular facility. Ask who dispenses, what quantity arrives, which injection supplies accompany it and how that quantity relates to the prescribed schedule. Also establish whom to contact about a delayed, damaged or incorrectly supplied order and the applicable reporting deadline. An advertised appointment interval does not establish pharmacy processing time or a replacement remedy.